HENLIUS (02696.HK): NMPA Clears HLX105 Phase 1 Solid Tumour IND

On 16 November 2026, HENLIUS (02696.HK) said the NMPA approved a Phase 1 IND for HLX105, an anti-PD-1 antibody-IL-2 fusion protein, for advanced solid tumours.

NewTimeSpace News: On 16 November 2026, Shanghai Henlius Biotech, Inc. (stock code: 2696) announced that the Investigational New Drug (IND) application for the phase 1 clinical trial of HLX105 for Injection (anti-PD-1 antibody-IL-2 variant fusion protein), independently developed by the Company for the treatment of advanced or metastatic solid tumours, has recently been approved by the National Medical Products Administration (NMPA).

HLX105 possesses the dual functions of blocking the PD-1/PD-L1 pathway and activating the IL-2 pathway. Its IL-2 arm retains affinity for IL-2Rα while significantly weakening binding to the IL-2Rβ/γ dimer and the human IL2Rα/β/γ trimer, thereby reducing peripheral toxicity; the PD-1 binding arm simultaneously blocks PD-1 and selectively delivers IL-2, transmitting IL-2R signalling to PD-1-positive T cells in cis, activating tumour-specific T cells and promoting their differentiation into more potent effector T cells for specific anti-tumour effects. Preclinical studies showed positive anti-tumour efficacy and a good safety profile.

As at the date of the announcement, no antibody fusion protein product targeting PD-1 and fused with an IL-2 variant has been approved for marketing globally. The announcement carries the warning statement under Rule 18A.05 of the Listing Rules that the Company cannot guarantee it will successfully develop and commercialise HLX105.

×
Share to WeChat

Open WeChat, use the "Scan", and share to my Moments.